218 results on '"Pillet, N."'
Search Results
102. The 5′ Repeat Elements of the Mouse Xist Gene Inhibit the Transcription of X-Linked Genes
- Author
-
Allaman-Pillet, N., primary, DJEMAÏ, A., additional, Bonny, C., additional, and Schorderet, D.F., additional
- Published
- 2001
- Full Text
- View/download PDF
103. Shell Structure and Nuclear High-K Isomers.
- Author
-
Quentin, P., Pillet, N., and Libert, J.
- Subjects
NUCLEAR shell theory ,NUCLEAR isomers ,PARTICLES (Nuclear physics) ,NEUTRON number ,ATOMIC number - Published
- 2000
104. TDF2 satellite propulsion system passivation
- Author
-
Pillet, N., primary, Gibek, I., additional, and Equios, P., additional
- Published
- 2000
- Full Text
- View/download PDF
105. First characterization of sd-shell nuclei with a multiconfiguration approach.
- Author
-
Bloas, J. Le, Pillet, N., Dupuis, M., Daugas, J. M., Robledo, L. M., Robin, C., and Zelevinsky, V. G.
- Subjects
- *
NUCLEAR spectroscopy , *NANOPARTICLES , *GROUND state (Quantum mechanics) , *QUADRUPOLE moments , *EXCITED states , *NUCLEAR shell theory - Abstract
In this work, we propose a new description of nuclear spectroscopy based on the analysis of a rather complete set of observables, using the multiparticle-multihole configuration mixing and the D1S Gogny interaction. The application to the even-even sd-shell nuclei, for both ground and 0+2, 1+1, 2+1, 2+2, 3+1, 3+2, 4+1 excited states, clearly shows the pertinence of this approach. The standard deviation to experiment is ~500 keV for two-nucleon separation energies and ~400 keV for excitation energies. The calculated magnetic dipole moments and B(M1) transition probabilities are in a very good agreement with experiment. Concerning the spectroscopic quadrupole moments and B(E2) transition probabilities, the experimental trends are systematically reproduced. Only a lack of quadrupole collectivity appears. A solution to improve this expected defect is suggested. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
106. Hybrid propulsion for small satellites analysis and tests
- Author
-
Lengelle, G., primary, Foucaud, R., additional, Godon, J., additional, Heslouin, A., additional, Lecourt, R., additional, Maisonneuve, Y., additional, and Pillet, N., additional
- Published
- 1999
- Full Text
- View/download PDF
107. Characterization of the promoter region of the mouse Xist gene.
- Author
-
Pillet, N, primary, Bonny, C, additional, and Schorderet, D F, additional
- Published
- 1995
- Full Text
- View/download PDF
108. Synthesis of 1,5-Anhydro-2-(N6-Cyclopentyladenin-9-Yl)-2-Deoxy-D-Altrohexitol
- Author
-
Verheggen, I., primary, Van Aerschot, A., additional, Pillet, N., additional, van der Wenden, E. M., additional, Ijzerman, A., additional, and Herdewijn, P., additional
- Published
- 1995
- Full Text
- View/download PDF
109. In Search of Acyclic Analogues as Universal Nucleosides in Degenerate Probes
- Author
-
Van Aerschot, A., primary, Hendrix, C., additional, Schepers, G., additional, Pillet, N., additional, and Herdewijn, P., additional
- Published
- 1995
- Full Text
- View/download PDF
110. An acyclic 5-nitroindazole nucleoside analogue as ambiguous nucleoside
- Author
-
Aerschot, A.Van, primary, Rozenski, J., additional, Loakes, D., additional, Pillet, N., additional, Schepers, G., additional, and Herdewijn, P., additional
- Published
- 1995
- Full Text
- View/download PDF
111. DESCRIPTION OF LIGHT NUCLEI (10 = Z,N = 18) WITHIN THE MULTIPARTICLE-MULTIHOLE GOGNY ENERGY DENSITY FUNCTIONAL.
- Author
-
Le Bloas, J., PILLET, N., DAUGAS, J.-M., and DUPUIS, M.
- Subjects
- *
ATOMIC nucleus , *DENSITY functionals , *QUADRUPOLE moments , *PROBABILITY theory , *QUADRUPOLES , *MAGNETIC moments - Abstract
In this work, we report a few examples of excitation energies, magnetic and quadrupole moments as well as B(M1) and B(E2) transition probabilities calculated within the multiparticle-multihole (mp-mh) con- figuration mixing approach [N. Pillet, J.-F. Berger, E. Caurier, Phys. Rev. C78, 024305 (2008); N. Pillet et al., Phys. Rev. C85, 044315 (2012)], for sd-shell even-even nuclei with 10 = Z, N = 18. The D1S Gogny effective interaction has been used. Only low-lying positive parity states have been considered. A very satisfactory agreement is obtained with experiment for energies, magnetic moments and B(M1) transition probabilities. The calculated B(E2) transition probabilities between 2+1 and 0+1 states, 4+1 and 2+1 states reproduce the experimental trends along the isotonic and isotopic chains with the good order of magnitude [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
112. VARIATIONAL MULTIPARTICLE-MULTIHOLE MIXING WITH THE D1S GOGNY FORCE.
- Author
-
PILLET, N., BERGER, J.-F., GIROD, M., and CAURIER, E.
- Subjects
- *
MEAN field theory , *PARTICLES (Nuclear physics) , *NUCLEAR physics , *NUCLEAR models , *NUCLEAR energy , *HAMILTONIAN systems - Abstract
Applying a variational multiparticle-multihole mixing method whose purpose is to include correlations beyond mean field in an unified way without particle number and Pauli violations, we investigate ground state properties of 22O nucleus, in the case of pairing-type correlations. The same interaction is used for the mean field and the residual part of the hamiltonian, namely, the density-dependent D1S Gogny force. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
113. In Search of Acyclic Analogues as Universal Nucleosides in Degenerate Probes.
- Author
-
Aerschot, A. Van, Hendrix, C., Schepers, G., Pillet, N., and Herdewijn, P.
- Published
- 1995
- Full Text
- View/download PDF
114. Synthesis of 1,5-Anhydro-2-( N -Cyclopentyladenin-9-Yl)-2-Deoxy-D- Altro hexitol.
- Author
-
Verheggen, I., Aerschot, A. Van, Pillet, N., van der Wenden, E. M., Ijzerman, A., and Herdewijn, P.
- Published
- 1995
- Full Text
- View/download PDF
115. In Search of Acyclic Analogues as Universal Nucleosides in Degenerate Probes
- Author
-
Van Aerschot, A., Hendrix, C., Schepers, G., Pillet, N., and Herdewijn, P.
- Abstract
Five acyclic nucleoside analogues with unnatural base moieties have been synthesized of which three successfully were incorporated into oligonucleotides. The acyclic analogue containing the base 5-nitroindazole was the least discriminating and should be further pursued for use as a universal nucleoside analogue.
- Published
- 1995
- Full Text
- View/download PDF
116. 1,5-Anhydrohexitol nucleoside analogues as new antiviral entities
- Author
-
Aerschot, A., Verheggen, I., Pillet, N., Snoeck, R., Graciela Andrei, Clercq, E., and Herdewijn, P.
117. The Front-End electronics for the LHCb scintillating fibres detector
- Author
-
Chanal, H., Albert Comerma, and Pillet, N.
- Subjects
Detectors and Experimental Techniques - Abstract
The LHCb detector will be upgraded during the next LHC shutdown in 2018/19 [ 1 ]. The tracker system will have a major overhaul. Its components will be replaced with new technologies in order to cope with the increased hit occupancy and radiation environment. A detector made of scintillating fibres read out by silicon photomultipliers (SiPM) is studied for this upgrade. Even if this technology has proven to achieve high efficiency and spatial resolution, its integration within a LHC experiment bears new challenges. This detector will consist of 12 planes of 5 to 6 layers of 250 m m fibres with an area of 5 6 m 2 . It leads to a total of 500k SiPM channels which need to be read out at 40 MHz. This article gives an overview of the R&D; status of the readout board and the PACIFIC chip. The readout board is connected to the SiPM on one side and to the experiment data-acquisition, experimental control system and services on the other side. The PACIFIC chip is a 128-channels ASIC which can be connected to one 128-channels SiPM without the need of any external component. It includes the analog signal processing and a 2 bits non-linear flash ADC for digitisation. The PACIFIC chip design features a very fast shaping ( 10 ns ) and the ability to cope with different SiPM suppliers with a power consumption below 8 mW per channel
118. Neutron-induced cross sections measurements via surrogate reactions: a way to determine new transmutation nuclear data for minor actinides
- Author
-
Aiche, M., Barreau, G., Boutoux, G., Czajkowski, S., Dassié, D., Haas, B., Jurado, B., Mathieu, L., Kessedjian, G., Eric Bauge, Meot, V., Roig, O., Gaudefroy, L., Taieb, J., Pillet, N., Faul, T., Olivier Serot, Gunsing, F., Olivier SEROT, Mas, Virginie, Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), Université Sciences et Technologies - Bordeaux 1-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), DAM Île-de-France (DAM/DIF), Direction des Applications Militaires (DAM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Département de Physique Nucléaire (ex SPhN) (DPHN), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Université Sciences et Technologies - Bordeaux 1 (UB)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), and Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[PHYS.NEXP] Physics [physics]/Nuclear Experiment [nucl-ex] ,[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
119. Detector concepts
- Author
-
Aarons, G., Abe, T., Abernathy, J., Ablikim, M., Abramowicz, H., Adey, D., Adloff, C., Adolphsen, C., Afanaciev, K., Agapov, I., Ahn, J. -K, Aihara, H., Akemoto, M., Del Carmenalabau, M., Albert, J., Albrecht, H., Albrecht, M., Alesini, D., Alexander, G., Alexander, J., Allison, W., Amann, J., Amirikas, R., An, Q., Anami, S., Ananthanarayan, B., Anderson, T., Andricek, L., Anduze, M., Anerella, M., Anfimov, N., Angal-Kalinin, D., Antipov, S., Antoine, C., Aoki, M., Aoza, A., Aplin, S., Appleby, R., Arai, Y., Araki, S., Arkan, T., Arnold, N., Arnold, R., Arnowitt, R., Artru, X., Arya, K., Aryshev, A., Asakawa, E., Asiri, F., Asner, D., Atac, M., Atoian, G., Attié, D., Augustin, J. -E, Augustine, D. B., Ayres, B., Aziz, T., Baars, D., Badaud, F., Baddams, N., Bagger, J., Bai, S., Bailey, D., Bailey, I. R., Baker, D., Balalykin, N. I., Balbuena, J. P., Baldy, J. -L, Ball, M., Ballestrero, A., Ballin, J., Baltay, C., Bambade, P., Ban, S., Band, H., Bane, K., Banerjee, B., Barbanotti, S., Barbareschi, D., Barbaro-Galtieri, A., Barber, D. P., Barbi, M., Bardin, D. Y., Barish, B., Barklow, T. L., Barlow, R., Barnes, V. E., Barone, M., Bartels, C., Bartsch, V., Basu, R., Battaglia, M., Batygin, Y., Baudot, J., Baur, U., Baynham, D. E., Beard, C., Bebek, C., Bechtle, P., Becker, U. J., Bedeschi, F., Bedjidian, M., Behera, P., Behnke, T., Bellantoni, L., Bellerive, A., Bellomo, P., Bentson, L. D., Benyamna, M., Bergauer, T., Berger, E., Bergholz, M., Beri, S., Berndt, M., Bernreuther, W., Bertolini, A., Besancon, M., Besson, A., Beteille, A., Bettoni, S., Beyer, M., Bhandari, R. K., Bharadwaj, V., Bhatnagar, V., Bhattacharya, S., Bhattacharyya, G., Bhattacherjee, B., Bhuyan, R., Bi, X. -J, Biagini, M., Bialowons, W., Biebel, O., Bieler, T., Bierwagen, J., Birch, A., Bisset, M., Biswal, S. S., Blackmore, V., Blair, G., Blanchard, G., Blazey, G., Blue, A., Blümlein, J., Boffo, C., Bohn, C., Boiko, V. I., Boisvert, V., Bondarchuk, E. N., Boni, R., Bonvicini, G., Boogert, S., Boonekamp, M., Boorman, G., Borras, K., Bortoletto, D., Bosco, A., Bosio, C., Bosland, P., Bosotti, A., Boudry, V., Boumediene, D. -E, Bouquet, B., Bourov, S., Bowden, G., Bower, G., Boyarski, A., Bozovic-Jelisavcic, I., Bozzi, C., Brachmann, A., Bradshaw, T. W., Brandt, A., Brasser, H. P., Brau, B., Brau, J. E., Breidenbach, M., Bricker, S., Brient, J. -C, Brock, I., Brodsky, S., Brooksby, C., Broome, T. A., Brown, D., Brownell, J. H., Bruchon, M., Brueck, H., Brummitt, A. J., Brun, N., Buchholz, P., Budagov, Y. A., Bulgheroni, A., Bulyak, E., Bungau, A., Bürger, J., Burke, D., Burkhart, C., Burrows, P., Burt, G., Burton, D., Büsser, K., Butler, J., Butterworth, J., Buzulutskov, A., Cabruja, E., Caccia, M., Cai, Y., Calcaterra, A., Caliier, S., Camporesi, T., Cao, J. -J, Cao, J. S., Capatina, O., Cappellini, C., Carcagno, R., Carena, M., Carloganu, C., Carosi, R., Carr, F. S., Carrion, F., Carter, H. F., Carter, J., Carwardine, J., Cassel, R., Cassell, R., Cavallari, G., Cavallo, E., Cembranos, J. A. R., Chakraborty, D., Chandez, F., Charles, M., Chase, B., Chattopadhyay, S., Chauveau, J., Chefdeville, M., Chehab, R., Chel, S., Chelkov, G., Chen, C., Chen, H. S., Chen, H. B., Chen, J. E., Chen, S. Y., Chen, S., Chen, X., Chen, Y. B., Cheng, J., Chevallier, M., Chi, Y. L., Chickering, W., Cho, G. -C, Cho, M. -H, Choi, J. -H, Choi, J. B., Choi, S. Y., Choi, Y. -I, Choudhary, B., Choudhury, D., Choudhury, S. R., Christian, D., Christian, G., Christophe, G., Chung, J. -H, Church, M., Ciborowski, J., Cihangir, S., Ciovati, G., Clarke, C., Clarke, D. G., Clarke, J. A., Clements, E., Coca, C., Coe, P., Cogan, J., Colas, P., Collard, C., Colledani, C., Combaret, C., Comerma, A., Compton, C., Constance, B., Conway, J., Cook, E., Cooke, P., Cooper, W., Corcoran, S., Cornat, R., Corner, L., Gil, E. C., Corvin, W. C., Ramusino, A. C., Cowan, R., Crawford, C., Cremaldi, L. M., Crittenden, J. A., Cussans, D., Cvach, J., Da Silva, W., Khah, H. D., Dabrowski, A., Dabrowski, W., Dadoun, O., Dai, J. P., Dainton, J., Daly, C., Damerell, C., Danilov, M., Daniluk, W., Daram, S., Datta, A., Dauncey, P., David, J., Davier, M., Davies, K. P., Dawson, S., Boer, W., Curtis, S., Groot, N., La Taille, C., Lira, A., Roeck, A., Sangro, R., Santis, S., Deacon, L., Deandrea, A., Klaus Dehmelt, Delagnes, E., Delahaye, J. -P, Delebecque, P., Delerue, N., Delferriere, O., Demarteau, M., Deng, Z., Denisov, Yu N., Densham, C. J., Desch, K., Deshpande, N., Devanz, G., Devetak, E., Dexter, A., Di Benedetto, V., Diéguez, Á, Diener, R., Dinh, N. D., Dixit, M., Dixit, S., Djouadi, A., Dolezal, Z., Dollan, R., Dong, D., Dong, H. Y., Dorfan, J., Dorokhov, A., Doucas, G., Downing, R., Doyle, E., Doziere, G., Drago, A., Dragt, A., Drake, G., Drásal, Z., Dreiner, H., Drell, P., Driouichi, C., Drozhdin, A., Drugakov, V., Du, S., Dugan, G., Duginov, V., Dulinski, W., Dulucq, F., Dutta, S., Dwivedi, J., Dychkant, A., Dzahini, D., Eckerlin, G., Edwards, H., Ehrenfeld, W., Ehrlichman, M., Ehrlichmann, H., Eigen, G., Elagin, A., Elementi, L., Eliasson, P., Ellis, J., Ellwood, G., Elsen, E., Emery, L., Enami, K., Endo, K., Enomoto, A., Eozénou, F., Erbacher, R., Erickson, R., Eyser, K. O., Fadeyev, V., Fang, S. X., Fant, K., Fasso, A., Giannelli, M. F., Fehlberg, J., Feld, L., Feng, J. L., Ferguson, J., Fernandez-Garcia, M., Fernandez-Hernando, J. L., Fiala, P., Fieguth, T., Finch, A., Finocchiaro, G., Fischer, P., Fisher, P., Fisk, H. E., Fitton, M. D., Fleck, I., Fleischer, M., Fleury, J., Flood, K., Foley, M., Ford, R., Fortin, D., Foster, B., Fourches, N., Francis, K., Frey, A., Frey, R., Friedsam, H., Frisch, J., Frishman, A., Fuerst, J., Fujii, K., Fujimoto, J., Fukuda, M., Fukuda, S., Funahashi, Y., Funk, W., Furletova, J., Furukawa, K., Furuta, F., Fusayasu, T., Fuster, J., Gadow, K., Gaede, F., Gaglione, R., Gai, W., Gajewski, J., Galik, R., Galkin, A., Galkin, V., Gallin-Martel, L., Gannaway, F., Gao, J. S., Gao, J., Gao, Y., Garbincius, P., Garcia-Tabares, L., Garren, L., Garrido, L., Garutti, E., Garvey, T., Garwin, E., Gascón, D., Gastal, M., Gatto, C., Gatto, R., Gay, P., Ge, L., Ge, M. Q., Ge, R., Geiser, A., Gellrich, A., Genat, J. -F, Geng, Z. Q., Gentile, S., Gerbick, S., Gerig, R., Ghosh, D. K., Ghosh, K., Gibbons, L., Giganon, A., Gillespie, A., Gillman, T., Ginzburg, I., Giomataris, I., Giunta, M., Gladkikh, P., Gluza, J., Godbole, R., Godfrey, S., Goldhaber, G., Goldstein, J., Gollin, G. D., Gonzalez-Sanchez, F. J., Goodrick, M., Gornushkin, Y., Gostkin, M., Gottschalk, E., Goudket, P., Eschrich, I. G., Gournaris, F., Graciani, R., Graf, N., Grah, C., Grancagnolo, F., Grandjean, D., Grannis, P., Grassellino, A., Graugés, E., Gray, S., Green, M., Greenhalgh, J., Greenshaw, T., Grefe, C., Gregor, I. -M, Grenier, G., Grimes, M., Grimm, T., Gris, P., Grivaz, J. -F, Groll, M., Gronberg, J., Grondin, D., Groom, D., Gross, E., Grunewald, M., Grupen, C., Grzelak, G., Gu, J., Gu, Y. -T, Guchait, M., Guiducci, S., Guler, A. M., Guler, H., Gulmez, E., Gunion, J., Guo, Z. Y., Gurtu, A., Ha, H. B., Haas, T., Haase, A., Haba, N., Haber, H., Haensel, S., Hagge, L., Hagura, H., Hajdu, C., Haller, G., Haller, J., Hallermann, L., Halyo, V., Hamaguchi, K., Hammond, L., Han, L., Han, T., Hand, L., Handu, V. K., Hano, H., Hansen, C., Hansen, J. D., Hansen, J. B., Hara, K., Harder, K., Hartin, A., Hartung, W., Hast, C., Hauptman, J., Hauschild, M., Hauviller, C., Havranek, M., Hawkes, C., Hawkings, R., Hayano, H., Hazumi, M., He, A., He, H. J., Hearty, C., Heath, H., Hebbeker, T., Hedberg, V., Hedin, D., Heifets, S., Heinemeyer, S., Heini, S., Helebrant, C., Helms, R., Heltsley, B., Henrot-Versille, S., Henschel, H., Hensel, C., Hermel, R., Herms, A., Herten, G., Hesselbach, S., Heuer, R. -D, Heusch, C. A., Hewett, J., Higashi, N., Higashi, T., Higashi, Y., Higo, T., Hildreth, M. D., Hiller, K., Hillert, S., Hillier, S. J., Himel, T., Himmi, A., Hinchliffe, I., Hioki, Z., Hirano, K., Hirose, T., Hisamatsu, H., Hisano, J., Hlaing, C. T., Hock, K. M., Hoeferkamp, M., Hohlfeld, M., Honda, Y., Hong, J., Hong, T. M., Honma, H., Horii, Y., Horvath, D., Hosoyama, K., Hostachy, J. -Y, Hou, M., Hou, W. -S, Howell, D., Hronek, M., Hsiung, Y. B., Hu, B., Hu, T., Huang, J. -Y, Huang, T. M., Huang, W. H., Huedem, E., Huggard, P., Hugonie, C., Hu-Guo, C., Huitu, K., Hwang, Y., Idzik, M., Ignatenko, A., Ignatov, F., Ikeda, H., Ikematsu, K., Ilicheva, T., Imbault, D., Imhof, A., Incagli, M., Ingbir, R., Inoue, H., Inoue, Y., Introzzi, G., Ioakeimidi, K., Ishihara, S., Ishikawa, A., Ishikawa, T., Issakov, V., Ito, K., Ivanov, V. V., Ivanov, V., Ivanyushenkov, Y., Iwasaki, M., Iwashita, Y., Jackson, D., Jackson, F., Jacobsen, B., Jaganathan, R., Jamison, S., Janssen, M. E., Jaramillo-Echeverria, R., Jaros, J., Jauffret, C., Jawale, S. B., Jeans, D., Jedziniak, R., Jeffery, B., Jehanno, D., Jenner, L. J., Jensen, C., Jensen, D. R., Jiang, H., Jiang, X. M., Jimbo, M., Jin, S., Jobe, R. K., Johnson, A., Johnson, E., Johnson, M., Johnston, M., Joireman, P., Jokic, S., Jones, J., Jones, R. M., Jongewaard, E., Jönsson, L., Joshi, G., Joshi, S. C., Jung, J. -Y, Junk, T., Juste, A., Kado, M., Kadyk, J., Käfer, D., Kako, E., Kalavase, P., Kalinin, A., Kalinowski, J., Kamitani, T., Kamiya, Y., Kamoshita, J. -I, Kananov, S., Kanaya, K., Kanazawa, K. -I, Kanemura, S., Kang, H. -S, Kang, W., Kanjial, D., Kapusta, F., Karataev, P., Karchin, P. E., Karlen, D., Karyotakis, Y., Kashikhin, V., Kashiwagi, S., Kasley, P., Katagiri, H., Kato, T., Kato, Y., Katzy, J., Kaukher, A., Kaur, M., Kawagoe, K., Kawamura, H., Kazakov, S., Kekelidze, V. D., Keller, L., Kelley, M., Kelly, M., Kennedy, K., Kephart, R., Keung, J., Khainovski, O., Khan, S. A., Khare, P., Khovansky, N., Kiesling, C., Kikuchi, M., Kilian, W., Killenberg, M., Kim, D., Kim, E. S., Kim, E. -J, Kim, G., Kim, H., Kim, H. -C, Kim, J., Kim, K. -J, Kim, K. S., Kim, P., Kim, S., Kim, S. -H, Kim, S. K., Kim, T. J., Kim, Y., Kim, Y. -K, Kimmitt, M., Kirby, R., Kircher, F., Kisielewska, D., Kittel, O., Klanner, R., Klebaner, A. L., Kleinwort, C., Klimkovich, T., Klinkby, E., Kluth, S., Knecht, M., Kneisel, P., Ko, I. S., Ko, K., Kobayashi, M., Kobayashi, N., Kobel, M., Koch, M., Kodys, P., Koetz, U., Kohrs, R., Kojima, Y., Kolanoski, H., Kolodziej, K., Kolomensky, Y. G., Komamiya, S., Kong, X. C., Konigsberg, J., Korbel, V., Koscielniak, S., Kostromin, S., Kowalewski, R., Kraml, S., Krammer, M., Krasnykh, A., Krautscheid, T., Krawczyk, M., Krebs, H. J., Krempetz, K., Kribs, G., Krishnagopal, S., Kriske, R., Kronfeld, A., Kroseberg, J., Kruchonak, U., Kruecker, D., Krüger, H., Krumpa, N. A., Krumshtein, Z., Kuang, Y. P., Kubo, K., Kuchler, V., Kudoh, N., Kulis, S., Kumada, M., Kumar, A., Kume, T., Kundu, A., Kurevlev, G., Kurihara, Y., Kuriki, M., Kuroda, S., Kuroiwa, H., Kurokawa, S. -I, Kusano, T., Kush, P. K., Kutschke, R., Kuznetsova, E., Kvasnicka, P., Kwon, Y., Labarga, L., Lacasta, C., Lackey, S., Lackowski, T. W., Lafaye, R., Lafferty, G., Lagorio, E., Laktineh, I., Lal, S., Laloum, M., Lam, B., Lancaster, M., Lander, R., Lange, W., Langenfeld, U., Langeveld, W., Larbalestier, D., Larsen, R., Lastovicka, T., Lastovicka-Medin, G., Latina, A., Latour, E., Laurent, L., Le, B. N., Le, D. N., Le Diberder, F., Le Dû, P., Lebbolo, H., Lebrun, P., Lecoq, J., Lee, S. -W, Lehner, F., Leibfritz, J., Lenkszus, F., Lesiak, T., Levy, A., Lewandowski, J., Leyh, G., Li, C., Li, C. S., Li, C. H., Li, D. Z., Li, G., Li, J., Li, S. P., Li, W. M., Li, W., Li, X. P., Li, X. -Q, Li, Y., Li, Z., Li, Z. Q., Liang, J. T., Liao, Y., Lilje, L., Lima, J. G., Lintern, A. J., Lipton, R., List, B., List, J., Liu, C., Liu, J. F., Liu, K. X., Liu, L. Q., Liu, S. Z., Liu, S. G., Liu, S., Liu, W., Liu, W. B., Liu, Y. P., Liu, Y. D., Lockyer, N., Logan, H. E., Logatchev, P. V., Lohmann, W., Lohse, T., Lola, S., Lopez-Virto, A., Loveridge, P., Lozano, M., Lu, C. -D, Lu, C., Lu, G. -L, Lu, W. H., Lubatti, H., Lucotte, A., Lundberg, B., Lundin, T., Luo, M., Luong, M., Luth, V., Lutz, B., Lutz, P., Lux, T., Luzniak, P., Lyapin, A., Lykken, J., Lynch, C., Ma, L., Ma, Q., Ma, W. -G, Macfarlane, D., Maciel, A., Macleod, A., Macnair, D., Mader, W., Magill, S., Magnan, A. -M, Maiheu, B., Maity, M., Majchrzak, M., Majumder, G., Makarov, R., Makowski, D., Malaescu, B., Mallik, C., Mallik, U., Malton, S., Malyshev, O. B., Malysheva, L. I., Mammosser, J., Mamta, Mamuzic, J., Manen, S., Manghisoni, M., Manly, S., Marcellini, F., Marcisovsky, M., Markiewicz, T. W., Marks, S., Marone, A., Marti, F., Martin, J. -P, Martin, V., Martin-Chassard, G., Martinez, M., Martinez-Rivero, C., Martsch, D., Martyn, H. -U, Maruyama, T., Masuzawa, M., Mathez, H., Matsuda, T., Matsumoto, H., Matsumoto, S., Matsumoto, T., Matsunaga, H., Mättig, P., Mattison, T., Mavromanolakis, G., Mawatari, K., Mazzacane, A., Mcbride, P., Mccormick, D., Mccormick, J., Mcdonald, K. T., Mcgee, M., Mcintosh, P., Mckee, B., Mcpherson, R. A., Meidlinger, M., Meier, K., Mele, B., Meller, B., Melzer-Pellmann, I. -A, Mendez, H., Mercer, A., Merkin, M., Meshkov, I. N., Messner, R., Metcalfe, J., Meyer, C., Meyer, H., Meyer, J., Meyer, N., Meyners, N., Michelato, P., Michizono, S., Mihalcea, D., Mihara, S., Mihara, T., Mikami, Y., Mikhailichenko, A. A., Milardi, C., Miller, D. J., Miller, O., Miller, R. J., Milstene, C., Mimashi, T., Minashvili, I., Miquel, R., Mishra, S., Mitaroff, W., Mitchell, C., Miura, T., Miyamoto, A., Miyata, H., Mjörnmark, U., Mnich, J., Moenig, K., Moffeit, K., Mokhov, N., Molloy, S., Monaco, L., Monasterio, P. R., Montanari, A., Moon, S. I., Moortgat-Pick, G. A., Freitas, P. M., Morel, F., Moretti, S., Morgunov, V., Mori, T., Morin, L., Morisseau, F., Morita, Y., Morozov, N., Morozumi, Y., Morse, W., Moser, H. -G, Moultaka, G., Mtingwa, S., Mudrinic, M., Mueller, A., Mueller, W., Muennich, A., Muhlleitner, M. M., Mukherjee, B., Mukhopadhyaya, B., Müller, T., Munro, M., Murayama, H., Muto, T., Myneni, G. R., Nabhiraj, P. Y., Nagaitsev, S., Nagamine, T., Nagano, A., Naito, T., Nakai, H., Nakajima, H., Nakamura, I., Nakamura, T., Nakanishi, T., Nakao, K., Nakao, N., Nakayoshi, K., Nam, S., Namito, Y., Namkung, W., Nantista, C., Napoly, O., Narain, M., Naroska, B., Nauenberg, U., Nayyar, R., Neal, H., Nelson, C., Nelson, J., Nelson, T., Nemecek, S., Neubauer, M., Neuffer, D., Newman, M. Q., Nezhevenko, O., Ng, C. -K, Nguyen, A. K., Nguyen, M., Thi, H. V. N., Niebuhr, C., Niehoff, J., Niezurawski, P., Nishitani, T., Nitoh, O., Noguchi, S., Nomerotski, A., Noonan, J., Norbeck, E., Nosochkov, Y., Notz, D., Nowak, G., Nowak, H., Noy, M., Nozaki, M., Nyffeler, A., Nygren, D., Oddone, P., O, J., Oh, J. -S, Oh, S. K., Ohkuma, K., Ohlerich, M., Ohmi, K., Ohnishi, Y., Ohsawa, S., Ohuchi, N., Oide, K., Okada, N., Okada, Y., Okamura, T., Okugi, T., Okumi, S., Okumura, K. -I, Olchevski, A., Oliver, W., Olivier, B., Olsen, J., Olsen, S., Olshevsky, A. G., Olsson, J., Omori, T., Onel, Y., Onengut, G., Ono, H., Onoprienko, D., Oreglia, M., Oren, W., Orimoto, T. J., Oriunno, M., Orlandea, M. C., Oroku, M., Orr, L. H., Orr, R. S., Oshea, V., Oskarsson, A., Osland, P., Ossetski, D., Österman, L., Ostiguy, F., Otono, H., Ottewell, B., Ouyang, Q., Padamsee, H., Padilla, C., Pagani, C., Palmer, M. A., Pam, W. M., Pande, M., Pande, R., Pandit, V. S., Pandita, P. N., Pandurovic, M., Pankov, A., Panzeri, N., Papandreou, Z., Paparella, R., Para, A., Park, H., Parker, B., Parkes, C., Parma, V., Parsa, Z., Parsons, J., Partridge, R., Pasquinelli, R., Pásztor, G., Paterson, E., Patrick, J., Patteri, P., Patterson, J. R., Pauletta, G., Paver, N., Pavlicek, V., Pawlik, B., Payet, J., Pchalek, N., Pedersen, J., Pei, G. X., Pei, S. L., Pelka, J., Pellegrini, G., Pellett, D., Peng, G. X., Penn, G., Penzo, A., Perry, C., Peskin, M., Peters, F., Petersen, T. C., Peterson, D., Peterson, T., Petterson, M., Pfeffer, H., Pfund, P., Phelps, A., Phi, Q., Phillips, J., Phinney, N., Piccolo, M., Piemontese, L., Pierini, P., Piggott, W. T., Pike, G., Pillet, N., Jayawardena, T. P., Piot, P., Pitts, K., Pivi, M., Plate, D., Pleier, M. -A, Poblaguev, A., Poehler, M., Poelker, M., Poffenberger, P., Pogorelsky, I., Poirier, F., Poling, R., Poole, M., Popescu, S., Popielarski, J., Pöschl, R., Postranecky, M., Potukochi, P. N., Prast, J., Prat, S., Preger, M., Prepost, R., Price, M., Proch, D., Puntambekar, A., Qin, Q., Qu, H. M., Quadt, A., Quesnel, J. -P, Radeka, V., Rahmat, R., Rai, S. K., Raimondi, P., Ramberg, E., Ranjan, K., Rao, S. V. L. S., Raspereza, A., Ratti, A., Ratti, L., Raubenheimer, T., Raux, L., Ravindran, V., Raychaudhuri, S., Re, V., Rease, B., Reece, C. E., Regler, M., Rehlich, K., Reichel, I., Reichold, A., Reid, J., Reid, R., Reidy, J., Reinhard, M., Renz, U., Repond, J., Resta-Lopez, J., Reuen, L., Ribnik, J., Rice, T., Richard, F., Riemann, S., Riemann, T., Riles, K., Riley, D., Rimbault, C., Rindani, S., Rinolfi, L., Risigo, F., Riu, I., Rizhikov, D., Rizzo, T., Rochford, J. H., Rodriguez, P., Roeben, M., Rolandi, G., Roodman, A., Rosenberg, E., Roser, R., Ross, M., Rossel, F., Rossmanith, R., Roth, S., Rougé, A., Rowe, A., Roy, A., Roy, S. B., Roy, S., Royer, L., Royole-Degieux, P., Royon, C., Ruan, M., Rubin, D., Ruehl, I., Jimeno, A. R., Ruland, R., Rusnak, B., Ryu, S. -Y, Sabbi, G. L., Sadeh, I., Sadygov, Z. Y., Saeki, T., Sagan, D., Sahni, V. C., Saini, A., Saito, K., Sajot, G., Sakanaka, S., Sakaue, K., Salata, Z., Salih, S., Salvatore, F., Samson, J., Sanami, T., Sanchez, A. L., Sands, W., Santic, J., Sanuki, T., Sapronov, A., Sarkar, U., Sasao, N., Satoh, K., Sauli, F., Saunders, C., Saveliev, V., Savoy-Navarro, A., Sawyer, L., Saxton, L., Schäfer, O., Schälicke, A., Schade, P., Schaetzel, S., Scheitrum, G., Schibler, É, Schindler, R., Schlösser, M., Schlueter, R. D., Schmid, P., Schmidt, R. S., Schneekloth, U., Schreiber, H. J., Schreiber, S., Schroeder, H., Schüler, K. P., Schulte, D., Schultz-Coulon, H. -C, Schumacher, M., Schumann, S., Schumm, B. A., Schwienhorst, R., Schwierz, R., Scott, D. J., Scuri, F., Sefkow, F., Sefri, R., Seguin-Moreau, N., Seidel, S., Seidman, D., Sekmen, S., Seletskiy, S., Senaha, E., Senanayake, R., Sendai, H., Sertore, D., Seryi, A., Settles, R., Sever, R., Shales, N., Shao, M., Shelkov, G. A., Shepard, K., Shepherd-Themistocleous, C., Sheppard, J. C., Shi, C. T., Shidara, T., Shim, Y. -J, Shimizu, H., Shimizu, Y., Shimogawa, T., Shin, S., Shioden, M., Shipsey, I., Shirkov, G., Shishido, T., Shivpuri, R. K., Shrivastava, P., Shulga, S., Shumeiko, N., Shuvalov, S., Si, Z., Siddiqui, A. M., Siegrist, J., Simon, C., Simrock, S., Sinev, N., Singh, B. K., Singh, J., Singh, P., Singh, R. K., Singh, S. K., Singini, M., Sinha, A. K., Sinha, N., Sinha, R., Sinram, K., Sissakian, A. N., Skachkov, N. B., Skrinsky, A., Slater, M., Slominski, W., Smiljanic, I., Smith, A. J. S., Smith, A., Smith, B. J., Smith, J., Smith, S., Smith, T., Snodgrass, W. N., Sobloher, B., Sohn, Y. -U, Solidum, R., Solyak, N., Son, D., Sonmez, N., Sopczak, A., Soskov, V., Spencer, C. M., Spentzouris, P., Speziali, V., Spira, M., Sprehn, D., Sridhar, K., Srivastava, A., St Lorant, S., Stahl, A., Stanek, R. P., Stanitzki, M., Stanley, J., Stefanov, K., Stein, W., Steiner, H., Stenlund, E., Stern, A., Sternberg, M., Stockinger, D., Stockton, M., Stoeck, H., Strachan, J., Strakhovenko, V., Strauss, M., Striganov, S. I., Strologas, J., Strom, D., Strube, J., Stupakov, G., Su, D., Sudo, Y., Suehara, T., Suehiro, T., Suetsugu, Y., Sugahara, R., Sugimoto, Y., Sugiyama, A., Suh, J. S., Sukovic, G., Sun, H., Sun, S., Sun, W., Sun, Y., Suszycki, L., Sutcliffe, P., Suthar, R. L., Suwada, T., Suzuki, A., Suzuki, C., Suzuki, S., Suzuki, T., Swent, R., Swientek, K., Swinson, C., Syresin, E., Szleper, M., Tadday, A., Takahashi, R., Takahashi, T., Takano, M., Takasaki, F., Takeda, S., Takenaka, T., Takeshita, T., Takubo, Y., Tanaka, M., Tang, C. X., Taniguchi, T., Tantawi, S., Tapprogge, S., Tartaglia, M. A., Tassielli, G. F., Tauchi, T., Tavian, L., Tawara, H., Taylor, G., Telnov, A. V., Telnov, V., Tenenbaum, P., Teodorescu, E., Terashima, A., Terracciano, G., Terunuma, N., Teubner, T., Teuscher, R., Theilacker, J., Thomson, M., Tice, J., Tigner, M., Timmermans, J., Titov, M., Toge, N., Tokareva, N. A., Tollefson, K., Tomasek, L., Tomovic, S., Tompkins, J., Tonutti, M., Topkar, A., Toprek, D., Toral, F., Torrence, E., Traversi, G., Trimpl, M., Tripathi, S. M., Trischuk, W., Trodden, M., Trubnikov, G. V., Tschirhart, R., Tskhadadze, E., Tsuchiya, K., Tsukamoto, T., Tsunemi, A., Tucker, R., Turchetta, R., Tyndel, M., Uekusa, N., Ueno, K., Umemori, K., Ummenhofer, M., Underwood, D., Uozumi, S., Urakawa, J., Urban, J., Uriot, D., Urner, D., Ushakov, A., Usher, T., Uzunyan, S., Vachon, B., Valerio, L., Valin, I., Valishev, A., Vamra, R., Graaf, H., Kooten, R., Zandbergen, G., Vanel, J. -C, Variola, A., Varner, G., Velasco, M., Velte, U., Velthuis, J., Vempati, S. K., Venturini, M., Vescovi, C., Videau, H., Vila, I., Vincent, P., Virey, J. -M, Visentin, B., Viti, M., Vo, T. C., Vogel, A., Vogt, H., Toerne, E., Vorozhtsov, S. B., Vos, M., Votava, M., Vrba, V., Wackeroth, D., Wagner, A., Wagner, C. E. M., Wagner, S., Wake, M., Walczak, R., Walker, N. J., Walkowiak, W., Wallon, S., Walsh, R., Walston, S., Waltenberger, W., Walz, D., Wang, C. E., Wang, C. H., Wang, D., Wang, F., Wang, G. W., Wang, H., Wang, J., Wang, J. Q., Wang, L., Wang, M. -Z, Wang, Q., Wang, S. H., Wang, X., Wang, X. -L, Wang, Y. F., Wang, Z., Wanzenberg, R., Ward, B., Ward, D., Warmbein, B., Warner, D. W., Warren, M., Washio, M., Watanabe, I., Watanabe, K., Watanabe, T., Watanabe, Y., Watson, N., Wattimena, N., Wayne, M., Weber, M., Weerts, H., Weiglein, G., Weiland, T., Weinzierl, S., Weise, H., Weisend, J., Wendt, M., Wendt, O., Wenzel, H., Wenzel, W. A., Wermes, N., Werthenbach, U., Wesseln, S., Wester, W., White, A., White, G. R., Wichmann, K., Wienemann, P., Wierba, W., Wilksen, T., Willis, W., Wilson, G. W., Wilson, J. A., Wilson, R., Wing, M., Winter, M., Wirth, B. D., Wolbers, S. A., Wolff, D., Wolski, A., Woodley, M. D., Woods, M., Woodward, M. L., Woolliscroft, T., Worm, S., Wormser, G., Wright, D., Wu, A., Wu, T., Wu, Y. L., Xella, S., Xia, G., Xia, L., Xiao, A., Xiao, L., Xie, J. L., Xing, Z. -Z, Xiong, L. Y., Xu, G., Xu, Q. J., Yajnik, U. A., Yakimenko, V., Yamada, R., Yamaguchi, H., Yamamoto, A., Yamamoto, H., Yamamoto, M., Yamamoto, N., Yamamoto, R., Yamamoto, Y., Yamanaka, T., Yamaoka, H., Yamashita, S., Yamazaki, H., Yan, W., Yang, H. -J, Yang, J. M., Yang, J., Yang, Z., Yano, Y., Yazgan, E., Yeh, G. P., Yilmaz, H., Yock, P., Yoda, H., Yoh, J., Yokoya, K., Yokoyama, H., York, R. C., Yoshida, M., Yoshida, T., Yoshioka, T., Young, A., Yu, C. H., Yu, J., Yu, X. M., Yuan, C., Yue, C. -X, Yue, J. H., Zacek, J., Zagorodnov, I., Zalesak, J., Zalikhanov, B., Zarnecki, A. F., Zawiejski, L., Zeitnitz, C., Zeller, M., Zerwas, D., Zerwas, P., Zeyrek, M., Zhai, J. Y., Zhang, B. C., Zhang, B., Zhang, C., Zhang, H., Zhang, J., Zhang, J. R., Zhang, L., Zhang, X., Zhang, Y., Zhang, Z., Zhao, H., Zhao, J. J., Zhao, J. X., Zhao, M. H., Zhao, S. C., Zhao, T., Zhao, T. X., Zhao, Z. T., Zhao, Z., Zhou, D. M., Zhou, F., Zhou, S., Zhu, S. H., Zhu, X. W., Zhukov, V., Zimmermann, F., Ziolkowski, M., Zisman, M. S., Zomer, F., Zong, Z. G., Zorba, O., and Zutshi, V.
120. Description of nuclear systems with a self-consistent configuration-mixing approach: Theory, algorithm, and application to the 12C test nucleus.
- Author
-
Robin, C., Pillet, N., Arteaga, D. Peña, and Berger, J.-F.
- Subjects
- *
PHYSICS periodicals , *NUCLEAR structure , *SELF-consistent field theory , *GREEN'S functions - Abstract
Background: Although self-consistent multiconfiguration methods have been used for decades to address the description of atomic and molecular many-body systems, only a few trials have been made in the context of nuclear structure. Purpose: This work aims at the development of such an approach to describe in a unified way various types of correlations in nuclei in a self-consistent manner where the mean-field is improved as correlations are introduced. The goal is to reconcile the usually set-apart shell-model and self-consistent mean-field methods. Method: This approach is referred to as "variational multiparticle-multihole configuration mixing method." It is based on a double variational principle which yields a set of two coupled equations that determine at the same time the expansion coefficients of the many-body wave function and the single-particle states. The solution of this problem is obtained by building a doubly iterative numerical algorithm. Results: The formalism is derived and discussed in a general context, starting from a three-body Hamiltonian. Links to existing many-body techniques such as the formalism of Green's functions are established. First applications are done using the two-body D1S Gogny effective force. The numerical procedure is tested on the 12C nucleus to study the convergence features of the algorithm in different contexts. Ground-state properties as well as single-particle quantities are analyzed, and the description of the first 2+ state is examined. Conclusions: The self-consistent multiparticle-multihole configuration mixing method is fully applied for the first time to the description of a test nucleus. This study makes it possible to validate our numerical algorithm and leads to encouraging results. To test the method further, we will realize in the second article of this series a systematic description of more nuclei and observables obtained by applying the newly developed numerical procedure with the same Gogny force. As raised in the present work, applications of the variational multiparticle-multihole configuration mixing method will, however, ultimately require the use of an extended and more constrained Gogny force. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
121. Cooper pair sizes in superfluid nuclei in a simplified model
- Author
-
Pillet, N [CEA/DAM/DIF, F-91297 Arpajon (France)]
- Published
- 2010
- Full Text
- View/download PDF
122. Delayed y-ray and conversion-electron spectroscopy of A = 97 fission fragments.
- Author
-
Rudigier, M., Simpson, G. S., Dauga, J. M., Blazhev, A., Fransen, C., Gey, G., Hackstein, M., Jolie, J., Köste, U., Malkiewicz, T., Materna, T., Pfeiffer, M., Ramdhan, M., Régis, J.-M., Rother, W., Thoma, T., Warr, N., Wilmsen, D., Le Bloas, J., and Pillet, N.
- Subjects
- *
VALENCE fluctuations , *MASS spectrometers , *ELECTRON spectroscopy , *HALF-life (Nuclear physics) , *ISOMERS , *SPIN excitations - Abstract
A delayed, 76.5-keV transition has been observed in coincidence with 97Rb at the Lohengrin mass spectrometer via y-ray and conversion-electron spectroscopy. The multipolarity of the delayed transition was determined to be El and its measured half-life is 5.1(4) /xs. Comparisons with the results of Hartree-Fock-Bogoliubov and quasiparticle-rotor model calculations allow a spin and parity of (1/2, 3/2)- to be assigned to this state. The isomer is likely to be one of the low-lying prolate-deformed 3/2- [312], or oblate-deformed 1/2- [321], 3/2- [321] quasiparticle excitations. A new decay branch of the (9/2+), 830.8-keV isomer of 97Sr has also been observed in the same experiment, allowing a spin of (5/2)+ to be assigned to the 522.5-keV state. This level is likely to have a high-seniority spherical configuration [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
123. Construction of Continuous Collective Energy Landscapes for Large Amplitude Nuclear Many-Body Problems.
- Author
-
Carpentier P, Pillet N, Lacroix D, Dubray N, and Regnier D
- Abstract
Several protocols are proposed to build continuous energy surfaces of many-body quantum systems, regarding both energy and states. The standard variational principle is augmented with constraints on state overlap, ensuring arbitrary precision on continuity. As an illustration, the lowest energy and excited state paths relevant for the ^{240}Pu asymmetric fission are studied. The scission is clearly signed, with a neutron excess in the neck, the ultimate glue before its rupture. Our approach can potentially connect any couple of Hilbert space states, which opens up new horizons for various applications.
- Published
- 2024
- Full Text
- View/download PDF
124. Premature Vertebral Mineralization in hmx1 -Mutant Zebrafish.
- Author
-
El Fersioui Y, Pinton G, Allaman-Pillet N, and Schorderet DF
- Subjects
- Animals, Calcification, Physiologic, Genes, Homeobox, Homeodomain Proteins genetics, Homeodomain Proteins metabolism, Bone Diseases genetics, Zebrafish genetics, Zebrafish metabolism, Zebrafish Proteins genetics, Zebrafish Proteins metabolism
- Abstract
H6 family homeobox 1 (HMX1) regulates multiple aspects of craniofacial development, and mutations in HMX1 are linked to an ocular defect termed oculoauricular syndrome of Schorderet-Munier-Franceschetti (OAS) (MIM #612109). Recently, additional altered orofacial features have been reported, including short mandibular rami, asymmetry of the jaws, and altered premaxilla. We found that in two mutant zebrafish lines termed hmx1
mut10 and hmx1mut150 , precocious mineralization of the proximal vertebrae occurred. Zebrafish hmx1mut10 and hmx1mut150 report mutations in the SD1 and HD domains, which are essential for dimerization and activity of hmx1 . In hmx1mut10 , the bone morphogenetic protein (BMP) antagonists chordin and noggin1 were downregulated, while bmp2b and bmp4 were highly expressed and specifically localized to the dorsal region prior to the initiation of the osteogenic process. The osteogenic promoters runx2b and spp1 were also upregulated. Supplementation with DMH1-an inhibitor of the BMP signaling pathway-at the specific stage in which bmp2b and bmp4 are highly expressed resulted in reduced vertebral mineralization, resembling the wildtype mineralization progress of the axial skeleton. These results point to a possible role of hmx1 as part of a complex gene network that inhibits bmp2b and bmp4 in the dorsal region, thus regulating early axial skeleton development.- Published
- 2022
- Full Text
- View/download PDF
125. New COL6A6 Variant Causes Autosomal Dominant Retinitis Pigmentosa in a Four-Generation Family.
- Author
-
Vaclavik V, Tiab L, Sun YJ, Mahajan VB, Moulin A, Allaman-Pillet N, Munier FL, and Schorderet DF
- Subjects
- Exons, Humans, Mutation, Missense, Pedigree, Collagen Type VI genetics, Cone-Rod Dystrophies genetics, Retinitis Pigmentosa diagnosis, Retinitis Pigmentosa genetics
- Abstract
Purpose: To report that variants in the gene for a large lamina basal component protein, COL6A6 (collagen type VI alpha 6 chain, Col6α6), linked to chromosome 3p22.1 causes retinitis pigmentosa (RP) in patients with autosomal dominant transmission (adRP)., Methods: A positional-cloning approach, whole exome sequencing, and modeling were used. The proband and several affected family members have been phenotyped and followed for over 12 years., Results: A heterozygous missense variant, c.509C>G (p. Ser170Cys) in exon 2 of COL6A6 (comprised of 36 exons and 2236 amino acids), was observed in a four- generation family and is likely to cause the adRP phenotype. It was identified in 10 affected members. All affected family members had a distinct phenotype: late-onset rod cone dystrophy, with good retained visual acuity, until their late 70s. Immunohistochemistry of human retina showed a dot-like signal at the base of the inner segments of photoreceptors and outer plexiform layer (OPL). The structural modeling of the N7 domain of Col6α6 suggests that the mutant might result in the abnormal cellular localization of collagen VI or malformation of collagen fibers resulting in the loss of its unique filament structure., Conclusions: COL6A6 is widely expressed in human tissues and evolutionary conserved. It is thought to interact with a range of extracellular matrix components. Our findings suggest that this form of RP has long-term useful central visual acuity and a mild progression, which are important considerations for patient counseling.
- Published
- 2022
- Full Text
- View/download PDF
126. Piperlongumine promotes death of retinoblastoma cancer cells.
- Author
-
Allaman-Pillet N and Schorderet DF
- Abstract
Retinoblastoma is the most common pediatric intraocular malignant tumor. While retinoblastoma initiation is triggered by the inactivation of both alleles of the retinoblastoma tumor suppressor gene ( RB1 ) in the developing retina, tumor progression requires additional epigenetic changes, retinoblastoma genomes being quite stable. Although the management of RB has recently improved, new therapeutic agents are necessary to improve the treatment of advanced forms of retinoblastoma. In this report, we analyzed the pro-death effect of piperlongumine (PL), a natural compound isolated from Piper longum L., on two human retinoblastoma cell lines, WERI-Rb and Y79. The effects of PL on cell proliferation, cell death and cell cycle were investigated. PL effectively inhibited cell growth, impacted the cell cycle by decreasing the level of cyclins and CDK1 and increasing CDKN1A and triggered a caspase-3 independant cell death process in which reactive oxygen species (ROS) production is a major player. Indeed, PL toxicity in retinoblastoma cell lines was inhibited by a ROS scavenger N-acetyl-l-cysteine (NAC) treatment. These findings suggest that PL reduces tumor growth and induces cell death by regulating the cell cycle., Competing Interests: CONFLICTS OF INTEREST The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper., (Copyright: © 2021 Allaman-Pillet and Schorderet.)
- Published
- 2021
- Full Text
- View/download PDF
127. Hmx1 regulates urfh1 expression in the craniofacial region in zebrafish.
- Author
-
El Fersioui Y, Pinton G, Allaman-Pillet N, and Schorderet DF
- Subjects
- Amino Acid Sequence, Animals, Animals, Genetically Modified metabolism, Dimerization, Embryo, Nonmammalian metabolism, Eye growth & development, Gene Expression Regulation, Developmental, Homeodomain Proteins chemistry, Homeodomain Proteins genetics, Mutagenesis, Promoter Regions, Genetic, Trans-Activators genetics, Zebrafish growth & development, Zebrafish Proteins chemistry, Zebrafish Proteins genetics, Eye metabolism, Homeodomain Proteins metabolism, Trans-Activators metabolism, Zebrafish metabolism, Zebrafish Proteins metabolism
- Abstract
H6 family homeobox 1 (HMX1) regulates multiple aspects of craniofacial development as it is widely expressed in the eye, peripheral ganglia and branchial arches. Mutations in HMX1 are linked to an ocular defect termed Oculo-auricular syndrome of Schorderet-Munier-Franceschetti (MIM #612109). We identified UHRF1 as a target of HMX1 during development. UHRF1 and its partner proteins actively regulate chromatin modifications and cellular proliferation. Luciferase assays and in situ hybridization analyses showed that HMX1 exerts a transcriptional inhibitory effect on UHRF1 and a modification of its expression pattern. Overexpression of hmx1 in hsp70-hmx1 zebrafish increased uhrf1 expression in the cranial region, while mutations in the hmx1 dimerization domains reduced uhrf1 expression. Moreover, the expression level of uhrf1 and its partner dnmt1 was increased in the eye field in response to hmx1 overexpression. These results indicate that hmx1 regulates uhrf1 expression and, potentially through regulating the expression of factors involved in DNA methylation, contribute to the development of the craniofacial region of zebrafish., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
128. Evidence for Coexisting Shapes through Lifetime Measurements in ^{98}Zr.
- Author
-
Singh P, Korten W, Hagen TW, Görgen A, Grente L, Salsac MD, Farget F, Clément E, de France G, Braunroth T, Bruyneel B, Celikovic I, Delaune O, Dewald A, Dijon A, Delaroche JP, Girod M, Hackstein M, Jacquot B, Libert J, Litzinger J, Ljungvall J, Louchart C, Gottardo A, Michelagnoli C, Müller-Gatermann C, Napoli DR, Otsuka T, Pillet N, Recchia F, Rother W, Sahin E, Siem S, Sulignano B, Togashi T, Tsunoda Y, Theisen C, and Valiente-Dobon JJ
- Abstract
The lifetimes of the first excited 2^{+}, 4^{+}, and 6^{+} states in ^{98}Zr were measured with the recoil-distance Doppler shift method in an experiment performed at GANIL. Excited states in ^{98}Zr were populated using the fission reaction between a 6.2 MeV/u ^{238}U beam and a ^{9}Be target. The γ rays were detected with the EXOGAM array in correlation with the fission fragments identified by mass and atomic number in the VAMOS++ spectrometer. Our result shows a very small B(E2;2_{1}^{+}→0_{1}^{+}) value in ^{98}Zr, thereby confirming the very sudden onset of collectivity at N=60. The experimental results are compared to large-scale Monte Carlo shell model and beyond-mean-field calculations. The present results indicate the coexistence of two additional deformed shapes in this nucleus along with the spherical ground state.
- Published
- 2018
- Full Text
- View/download PDF
129. Corrigendum: Identifying mutations in Tunisian families with retinal dystrophy.
- Author
-
Habibi I, Chebil A, Falfoul Y, Allaman-Pillet N, Kort F, Schorderet DF, and Matri LE
- Published
- 2017
- Full Text
- View/download PDF
130. Mutations in the Spliceosome Component CWC27 Cause Retinal Degeneration with or without Additional Developmental Anomalies.
- Author
-
Xu M, Xie YA, Abouzeid H, Gordon CT, Fiorentino A, Sun Z, Lehman A, Osman IS, Dharmat R, Riveiro-Alvarez R, Bapst-Wicht L, Babino D, Arno G, Busetto V, Zhao L, Li H, Lopez-Martinez MA, Azevedo LF, Hubert L, Pontikos N, Eblimit A, Lorda-Sanchez I, Kheir V, Plagnol V, Oufadem M, Soens ZT, Yang L, Bole-Feysot C, Pfundt R, Allaman-Pillet N, Nitschké P, Cheetham ME, Lyonnet S, Agrawal SA, Li H, Pinton G, Michaelides M, Besmond C, Li Y, Yuan Z, von Lintig J, Webster AR, Le Hir H, Stoilov P, Amiel J, Hardcastle AJ, Ayuso C, Sui R, Chen R, Allikmets R, and Schorderet DF
- Subjects
- Adolescent, Animals, Child, Child, Preschool, Cyclophilins metabolism, Female, Humans, Male, Mice, Pedigree, Peptidylprolyl Isomerase metabolism, Young Adult, Abnormalities, Multiple genetics, Cyclophilins genetics, Mutation, Peptidylprolyl Isomerase genetics, Retinal Degeneration genetics
- Abstract
Pre-mRNA splicing factors play a fundamental role in regulating transcript diversity both temporally and spatially. Genetic defects in several spliceosome components have been linked to a set of non-overlapping spliceosomopathy phenotypes in humans, among which skeletal developmental defects and non-syndromic retinitis pigmentosa (RP) are frequent findings. Here we report that defects in spliceosome-associated protein CWC27 are associated with a spectrum of disease phenotypes ranging from isolated RP to severe syndromic forms. By whole-exome sequencing, recessive protein-truncating mutations in CWC27 were found in seven unrelated families that show a range of clinical phenotypes, including retinal degeneration, brachydactyly, craniofacial abnormalities, short stature, and neurological defects. Remarkably, variable expressivity of the human phenotype can be recapitulated in Cwc27 mutant mouse models, with significant embryonic lethality and severe phenotypes in the complete knockout mice while mice with a partial loss-of-function allele mimic the isolated retinal degeneration phenotype. Our study describes a retinal dystrophy-related phenotype spectrum as well as its genetic etiology and highlights the complexity of the spliceosomal gene network., (Copyright © 2017 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
131. Bigh3 silencing increases retinoblastoma tumor growth in the murine SV40-TAg-Rb model.
- Author
-
Allaman-Pillet N, Oberson A, and Schorderet DF
- Subjects
- Animals, Apoptosis genetics, Blotting, Western, Cyclin-Dependent Kinases genetics, Cyclin-Dependent Kinases metabolism, Extracellular Matrix Proteins metabolism, Humans, MAP Kinase Signaling System genetics, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Microscopy, Fluorescence, Retinal Neoplasms metabolism, Retinal Neoplasms pathology, Retinal Pigment Epithelium metabolism, Retinal Pigment Epithelium pathology, Retinoblastoma metabolism, Retinoblastoma pathology, Retinoblastoma Protein genetics, Retinoblastoma Protein metabolism, Reverse Transcriptase Polymerase Chain Reaction, Transforming Growth Factor beta metabolism, Tumor Burden genetics, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins metabolism, Antigens, Polyomavirus Transforming genetics, Disease Models, Animal, Extracellular Matrix Proteins genetics, Retinal Neoplasms genetics, Retinoblastoma genetics, Transforming Growth Factor beta genetics
- Abstract
BIGH3, a secreted protein of the extracellular matrix interacts with collagen and integrins on the cell surface. BIGH3 can have opposing functions in cancer, acting either as tumor suppressor or promoter by enhancing tumor progression and angiogenesis. In the eye, BIGH3 is expressed in the cornea and the retinal pigment epithelium and could impact on the development of retinoblastoma, the most common paediatric intraocular neoplasm. Retinoblastoma initiation requires the inactivation of both alleles of the RB1 tumor suppressor gene in the developing retina and tumor progression involves additional genomic changes. To determine whether BIGH3 affects retinoblastoma development, we generated a retinoblastoma mouse model with disruption of the Bigh3 genomic locus. Bigh3 silencing in these mice resulted in enhanced tumor development in the retina. A decrease in apoptosis is involved in the initial events of tumorigenesis, followed by an increased activity of the pro-survival ERK pathway as well as an upregulation of cyclin-dependent kinases (CDKs). Taken together, these data suggest that BIGH3 acts as a tumor suppressor in the retina.
- Published
- 2017
- Full Text
- View/download PDF
132. Identifying mutations in Tunisian families with retinal dystrophy.
- Author
-
Habibi I, Chebil A, Falfoul Y, Allaman-Pillet N, Kort F, Schorderet DF, and El Matri L
- Subjects
- Adult, Base Sequence, Chromosome Segregation genetics, Cohort Studies, Exons genetics, Family, Female, Fundus Oculi, Genome, Human, Homozygote, Humans, Male, Pedigree, RNA Splicing genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Retinal Dystrophies genetics, Tunisia, DNA Mutational Analysis, Mutation genetics
- Abstract
Retinal dystrophies (RD) are a rare genetic disorder with high genetic heterogeneity. This study aimed at identifying disease-causing variants in fifteen consanguineous Tunisian families. Full ophthalmic examination was performed. Index patients were subjected to IROme analysis or whole exome sequencing followed by homozygosity mapping. All detected variations were confirmed by direct Sanger sequencing. Mutation analysis in our patients revealed two compound heterozygous mutations p.(R91W);(V172D) in RPE65, and five novel homozygous mutations: p.R765C in CNGB1, p.H337R in PDE6B, splice site variant c.1129-2A > G and c.678_681delGAAG in FAM161A and c.1133 + 3_1133 + 6delAAGT in CERKL. The latter mutation impacts pre-mRNA splicing of CERKL. The other changes detected were six previously reported mutations in CNGB3 (p.R203*), ABCA4 (p.W782*), NR2E3 (p.R311Q), RPE65 (p.H182Y), PROM1 (c.1354dupT) and EYS (c.5928-2A > G). Segregation analysis in each family showed that all affected individuals were homozygotes and unaffected individuals were either heterozygote carriers or homozygous wild type allele. These results confirm the involvement of a large number of genes in RD in the Tunisian population.
- Published
- 2016
- Full Text
- View/download PDF
133. Tgfbi/Bigh3 silencing activates ERK in mouse retina.
- Author
-
Allaman-Pillet N, Oberson A, Bustamante M, Tasinato A, Hummler E, and Schorderet DF
- Subjects
- Animals, Apoptosis, Blotting, Southern, Cyclin D1 metabolism, Enzyme Activation, Extracellular Matrix Proteins metabolism, Female, Fluorescent Antibody Technique, Indirect, Genotyping Techniques, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Real-Time Polymerase Chain Reaction, Retina pathology, Retinal Pigment Epithelium metabolism, Reverse Transcriptase Polymerase Chain Reaction, Transforming Growth Factor beta metabolism, Extracellular Matrix Proteins genetics, Extracellular Signal-Regulated MAP Kinases metabolism, Gene Silencing physiology, Retina enzymology, Transforming Growth Factor beta genetics
- Abstract
BIGH3 is a secreted protein, part of the extracellular matrix where it interacts with collagen and integrins on the cell surface. BIGH3 can play opposing roles in cancer, acting as either tumor suppressor or promoter, and its mutations lead to different forms of corneal dystrophy. Although many studies have been carried out, little is known about the physiological role of BIGH3. Using the cre-loxP system, we generated a mouse model with disruption of the Bigh3 genomic locus. Bigh3 silencing did not result in any apparent phenotype modifications, the mice remained viable and fertile. We were able to determine the presence of BIGH3 in the retinal pigment epithelium (RPE). In the absence of BIGH3, a transient decrease in the apoptotic process involved in retina maturation was observed, leading to a transient increase in the INL thickness at P15. This phenomenon was accompanied by an increased activity of the pro-survival ERK pathway., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
134. BIRO1, a cell-permeable BH3 peptide, promotes mitochondrial fragmentation and death of retinoblastoma cells.
- Author
-
Allaman-Pillet N, Oberson A, and Schorderet DF
- Subjects
- Animals, Apoptosis drug effects, Apoptosis Regulatory Proteins genetics, Bcl-2-Like Protein 11, Caspases genetics, Cell Line, Tumor, Cell Survival drug effects, Humans, Membrane Proteins genetics, Mice, Mice, Transgenic, Mitochondria drug effects, Mitochondria genetics, Mitochondria pathology, Peptide Fragments genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Proto-Oncogene Proteins c-bcl-2 genetics, Retinoblastoma pathology, Retinoblastoma Protein genetics, Signal Transduction drug effects, Apoptosis genetics, Apoptosis Regulatory Proteins administration & dosage, Membrane Proteins administration & dosage, Peptide Fragments administration & dosage, Proto-Oncogene Proteins administration & dosage, Retinoblastoma genetics
- Abstract
Unlabelled: Retinoblastoma is the most common pediatric intraocular neoplasm. While retinoblastoma development requires the inactivation of both alleles of the retinoblastoma tumor suppressor gene (RB1) in the developing retina, additional genomic changes are involved in tumor progression, which progressively lead to resistance of tumor cells to death. Therapeutics acting at very downstream levels of death signaling pathways should therefore be interesting in killing retinoblastoma cells. The BH3-only proteins promote apoptosis by modulating the interaction between the pro- and antiapoptotic members of the BCL2 protein family, and this effect can be recapitulated by the BH3 domains. This report analyzes the effect of various BH3 peptides, corresponding to different BH3-only proteins, on two retinoblastoma cell lines, Y79 and WERI-Rb, as well as on the photoreceptor cell line 661W. The BH3 peptide BIRO1, derived from the BCL2L11 death domain, was very effective in promoting Y79 and WERI-Rb cell death without affecting the 661W photoreceptor cells. This cell death was efficient even in absence of BAX and was shown to be caspase independent. While ROS production or AIF release was not detected from mitochondria of treated cells, BIRO1 initiated mitochondria fragmentation in a short period of time following treatment., Implications: The BIRO1 peptide is highly effective at killing retinoblastoma cells and has potential as a peptidomimetic., (©2014 American Association for Cancer Research.)
- Published
- 2015
- Full Text
- View/download PDF
135. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
- Author
-
Allaman-Pillet N, Oberson A, Munier F, and Schorderet DF
- Subjects
- Animals, Blotting, Western, Caspase 3 metabolism, Caspase 7 metabolism, Disease Models, Animal, Electrophoresis, Polyacrylamide Gel, Fluorescent Antibody Technique, Indirect, Humans, Mice, Mice, Transgenic, Piperazines pharmacology, Proto-Oncogene Proteins c-bcl-2 metabolism, Reactive Oxygen Species metabolism, Retinal Neoplasms metabolism, Retinoblastoma metabolism, Tumor Cells, Cultured, bcl-X Protein metabolism, Antineoplastic Agents pharmacology, Apoptosis drug effects, Biphenyl Compounds pharmacology, Nitrophenols pharmacology, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors, Retinal Neoplasms pathology, Retinoblastoma pathology, Sulfonamides pharmacology, bcl-X Protein antagonists & inhibitors
- Abstract
Purpose: Retinoblastoma is a malignant tumor that usually develops in early childhood. During retinoblastoma spreading, RB1 gene inactivation is followed by additional genomic modifications which progressively lead to resistance of tumor cells to death. Drugs that act at downstream levels of death signaling pathways should therefore be interesting in killing retinoblastoma cells. ABT-737, a BH3 mimetic molecule effective at the mitochondrial level, has been shown to induce apoptosis in different human tumoral cell lines as well as in primary patient-derived cells, and in a mouse xenograph model., Methods: In this report, we analyzed the pro-death effect of ABT-737 on two human retinoblastoma cell lines, Y79 and WERI-Rb, as well as on the mouse photoreceptor cell line 661W., Results: We observed that ABT-737 was very effective as a single agent in inducing human WERI-Rb cells apoptosis without affecting the mouse 661W photoreceptor cells. However human Y79 cells were resistant to ABT-737, as a probable consequence of the absence of Bax. The high sensitivity of WERI-Rb to ABT-737 can be increased by downregulating Mcl-1 using the proteasome inhibitor MG-132. Preliminary analysis in primary mouse retinoblastoma tumoral cell lines predicts high sensitivity to ABT-737., Conclusion: Our data suggest that ABT-737 or related compounds could be a highly effective drug in the treatment of some retinoblastomas.
- Published
- 2013
- Full Text
- View/download PDF
136. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
- Author
-
Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, and Hermine O
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Benzamides, Depression epidemiology, Female, Humans, Male, Mastocytosis physiopathology, Middle Aged, Piperidines, Pyridines, Thiazoles adverse effects, Thiazoles therapeutic use, Young Adult, Depression diagnosis, Depression drug therapy, Mastocytosis drug therapy, Mastocytosis psychology
- Abstract
Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Our objective was to determine the prevalence and to describe features of depression in a large cohort of mastocytosis patients (n = 288) and to investigate the therapeutic impact of the protein kinase inhibitor masitinib in depression symptoms. The description of depression was based on the analysis of a database with Hamilton scores using Principal Component Analysis (PCA). Efficacy of masitinib therapy was evaluated using non parametric Wilcoxon test for paired data within a three months period (n = 35). Our results show that patients with indolent mastocytosis present an elevated prevalence of depression (64%). Depression was moderate in 56% but severe in 8% of cases. Core symptoms (such as psychic anxiety, depressed mood, work and interests) characterized depression in mastocytosis patients. Masitinib therapy was associated with significant improvement (67% of the cases) of overall depression, with 75% of recovery cases. Global Quality of Life slightly improved after masitinib therapy and did not predicted depression improvement. In conclusion, depression is very frequent in mastocytosis patients and masitinib therapy is associated with the reduction its psychic experiences. We conclude that depression in mastocytosis may originate from processes related to mast cells activation. Masitinib could therefore be a useful treatment for mastocytosis patients with depression and anxiety symptoms.
- Published
- 2011
- Full Text
- View/download PDF
137. Improvement of psychometric properties of a scale measuring inpatient satisfaction with care: a better response rate and a reduction of the ceiling effect.
- Author
-
Moret L, Nguyen JM, Pillet N, Falissard B, Lombrail P, and Gasquet I
- Subjects
- Adult, Aged, Aged, 80 and over, Factor Analysis, Statistical, France, Humans, Middle Aged, Principal Component Analysis, Psychometrics standards, Reproducibility of Results, Research Design, Hospitals standards, Patient Satisfaction statistics & numerical data, Psychometrics methods, Quality Indicators, Health Care statistics & numerical data, Surveys and Questionnaires standards
- Abstract
Background: The objective was to solve two problems of an already validated scale measuring inpatient opinion on care: 1) a high non-response rate for some items due to the "not applicable" response option and 2) a skewed score distribution with high ceiling effect., Methods: The EQS-H scale ("échelle de qualité des soins en hospitalisation") comprised 26 items and 2 sub-scales of 13 items each, 'quality of medical information' (MI) and 'relationships with staff and daily routine' (RS). Three studies were conducted: a first mono-centre study (n = 552, response rate = 83.4%, self-completion of the scale the day before discharge) to construct a shorter version of the scale without the items with high non-response rate and maintaining those useful to ensure good internal validity (construct, convergent and divergent) and reliability; a second mono-centre study (n = 1246, response rate = 77.9%, self-completion of the scale before discharge) to confirm psychometric properties of the new version; a third multi-centre national study (n = 886, response rate 41.7%, self-completion at home 15 days after discharge) to test a new response pattern in order to reduce ceiling effect., Results: Six items having a non-response rate >20% were deleted, increasing rates of exhaustive response to all items from 15% to 48%. Factorial analysis supported the evidence for removing 4 more items to ensure good internal validity and reliability of the new version. These good results (initial variance explained: 43%; Cronbach's alpha: 0.80 (MI) and 0.81 (RS)) were confirmed by the second study. The new response format produced a normalisation of the 2 scores with a large decrease in ceiling effect (25% to 4% for MI subscale and 61% to 8% for RS). Psychometric properties of the final version were excellent: the 2 subscales (8 items each) explained 66% of the variance in principal component analysis, Cronbach's alpha were respectively 0.92 (MI) and 0.93 (RS)., Conclusion: The new version of the EQS-H has better psychometric properties than the previous one. Rates of missing values are lower, and score distribution is normalized. An English version of this scale focused on quality of medical information delivered and on relationship with staff already exists, and this could be useful to conduct cross-cultural studies of health care service quality.
- Published
- 2007
- Full Text
- View/download PDF
138. Cell-permeable peptides induce dose- and length-dependent cytotoxic effects.
- Author
-
Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladrière L, Allaman-Pillet N, Poirot O, Kellenberger S, Beckmann JS, Eizirik DL, Bonny C, and Maurer F
- Subjects
- Animals, Apoptosis drug effects, Cell Survival drug effects, Dose-Response Relationship, Drug, Metabolic Clearance Rate, Molecular Weight, Peptides chemistry, Rats, Cell Membrane Permeability drug effects, Cell Membrane Permeability physiology, Insulin-Secreting Cells cytology, Insulin-Secreting Cells drug effects, Peptides administration & dosage, Peptides pharmacokinetics
- Abstract
We have explored the threshold of tolerance of three unrelated cell types to treatments with potential cytoprotective peptides bound to Tat(48-57) and Antp(43-58) cell-permeable peptide carriers. Both Tat(48-57) and Antp(43-58) are well known for their good efficacy at crossing membranes of different cell types, their overall low toxicity, and their absence of leakage once internalised. Here, we show that concentrations of up to 100 microM of Tat(48-57) were essentially harmless in all cells tested, whereas Antp(43-58) was significantly more toxic. Moreover, all peptides bound to Tat(48-57) and Antp(43-58) triggered significant and length-dependent cytotoxicity when used at concentrations above 10 microM in all but one cell types (208F rat fibroblasts), irrespective of the sequence of the cargo. Absence of cytotoxicity in 208F fibroblasts correlated with poor intracellular peptide uptake, as monitored by confocal laser scanning fluorescence microscopy. Our data further suggest that the onset of cytotoxicity correlates with the activation of two intracellular stress signalling pathways, namely those involving JNK, and to a lesser extent p38 mitogen-activated protein kinases. These responses are of particular concern for cells that are especially sensitive to the activation of stress kinases. Collectively, these results indicate that in order to avoid unwanted and unspecific cytotoxicity, effector molecules bound to Tat(48-57) should be designed with the shortest possible sequence and the highest possible affinity for their binding partners or targets, so that concentrations below 10 microM can be successfully applied to cells without harm. Considering that cytotoxicity associated to Tat(48-57)- and Antp(43-58) bound peptide conjugates was not restricted to a particular type of cells, our data provide a general framework for the design of cell-penetrating peptides that may apply to broader uses of intracellular peptide and drug delivery.
- Published
- 2007
- Full Text
- View/download PDF
139. Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysates.
- Author
-
Guenat S, Rouleau N, Bielmann C, Bedard J, Maurer F, Allaman-Pillet N, Nicod P, Bielefeld-Sévigny M, Beckmann JS, Bonny C, Bossé R, and Roduit R
- Subjects
- Binding Sites, Binding, Competitive, Cell Line, Dose-Response Relationship, Drug, Humans, MAP Kinase Kinase 4 metabolism, Combinatorial Chemistry Techniques methods, Drug Evaluation, Preclinical methods, Enzyme Inhibitors chemistry, Protein Kinases metabolism
- Abstract
Protein kinases are directly implicated in many human diseases; therefore, kinase inhibitors show great promises as new therapeutic drugs. In an effort to facilitate the screening and the characterization of kinase inhibitors, a novel application of the AlphaScreen technology was developed to monitor JNK activity from (1) purified kinase preparations and (2) endogenous kinase from cell lysates preactivated with different cytokines. The authors confirmed that both adenosine triphosphate (ATP) competitive as well as peptide-based JNK inhibitors were able to block the activity of both recombinant and HepG2 endogenous JNK activity. Using the same luminescence technique adapted for binding studies, the authors characterized peptide inhibitor mechanisms by measuring the binding affinity of the inhibitors for JNK. Because of the versatility of the technology, this cell-based JNK kinase assay could be adapted to other kinases and would represent a powerful tool to evaluate endogenous kinase activity and test a large number of potential inhibitors in a more physiologically relevant environment.
- Published
- 2006
- Full Text
- View/download PDF
140. A unique set of SH3-SH3 interactions controls IB1 homodimerization.
- Author
-
Kristensen O, Guenat S, Dar I, Allaman-Pillet N, Abderrahmani A, Ferdaoussi M, Roduit R, Maurer F, Beckmann JS, Kastrup JS, Gajhede M, and Bonny C
- Subjects
- Adaptor Proteins, Signal Transducing chemistry, Adaptor Proteins, Signal Transducing genetics, Amino Acid Substitution, Cell Line, Crystallography, X-Ray, Dimerization, Glucose Transporter Type 2 metabolism, Humans, Insulin Secretion, MAP Kinase Kinase 4 chemistry, Neurons metabolism, Point Mutation, src Homology Domains genetics, Adaptor Proteins, Signal Transducing metabolism, Gene Expression Regulation physiology, Insulin metabolism, Insulin-Secreting Cells metabolism, MAP Kinase Kinase 4 metabolism
- Abstract
Islet-brain 1 (IB1 or JIP-1) is a scaffold protein that interacts with components of the c-Jun N-terminal kinase (JNK) signal-transduction pathway. IB1 is expressed at high levels in neurons and in pancreatic beta-cells, where it controls expression of several insulin-secretory components and secretion. IB1 has been shown to homodimerize, but neither the molecular mechanisms nor the function of dimerization have yet been characterized. Here, we show that IB1 homodimerizes through a novel and unique set of Src homology 3 (SH3)-SH3 interactions. X-ray crystallography studies show that the dimer interface covers a region usually engaged in PxxP-mediated ligand recognition, even though the IB1 SH3 domain lacks this motif. The highly stable IB1 homodimer can be significantly destabilized in vitro by three individual point mutations directed against key residues involved in dimerization. Each mutation reduces IB1-dependent basal JNK activity in 293T cells. Impaired dimerization also results in a reduction in glucose transporter type 2 expression and in glucose-dependent insulin secretion in pancreatic beta-cells. Taken together, these results indicate that IB1 homodimerization through its SH3 domain has pleiotropic effects including regulation of the insulin secretion process.
- Published
- 2006
- Full Text
- View/download PDF
141. Antitumorigenic effect of proteasome inhibitors on insulinoma cells.
- Author
-
Størling J, Allaman-Pillet N, Karlsen AE, Billestrup N, Bonny C, and Mandrup-Poulsen T
- Subjects
- Acetylcysteine pharmacology, Adaptor Proteins, Signal Transducing antagonists & inhibitors, Animals, Apoptosis drug effects, Binding Sites, Cell Line, Tumor, Insulinoma pathology, JNK Mitogen-Activated Protein Kinases metabolism, Leupeptins pharmacology, Mice, Pancreatic Neoplasms pathology, Rats, Signal Transduction drug effects, Tumor Suppressor Protein p53 metabolism, Acetylcysteine analogs & derivatives, Antineoplastic Agents pharmacology, Cysteine Proteinase Inhibitors pharmacology, Insulinoma drug therapy, Pancreatic Neoplasms drug therapy, Proteasome Inhibitors
- Abstract
Malignant insulinoma is a critical cancer form with a poor prognosis. Because cure by surgery is infrequent, effective chemotherapy is in demand. Induction of cell death in tumor cells by proteasome inhibitors is emerging as a potential strategy in cancer therapy. Here we investigated whether inhibition of the proteasome has an antitumorigenic potential in insulinoma cells. Exposure of mouse betaTC3 insulinoma cells to the proteasome inhibitor N-Acetyl-Leu-Leu-Nle-CHO (ALLN) reduced cell viability, activated caspase-3, induced apoptosis, and suppressed insulin release. Treatment with ALLN also resulted in phosphorylation of c-jun N-terminal kinase (JNK) and an increase in in vitro phosphorylation of c-jun. In insulinoma cells with impaired JNK signaling, ALLN-induced apoptosis was significantly suppressed. Another proteasome inhibitor, lactacystin, also stimulated JNK activation, caused activation of caspase-3, suppressed cell viability, and induced apoptosis in betaTC3 and rat INS-1E cells. Both ALLN and lactacystin caused a marked decrease in the cellular amount of the JNK scaffold protein JNK-interacting protein 1/islet-brain-1. In primary pancreatic rat islet cells, proteasome inhibition reduced insulin secretion but had no impact on cell viability and even partially protected against the toxic effect of proinflammatory cytokines. Our findings demonstrate that proteasome inhibitors possess antitumorigenic and antiinsulinogenic effects on insulinoma cells.
- Published
- 2005
- Full Text
- View/download PDF
142. Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure.
- Author
-
Abdelli S, Ansite J, Roduit R, Borsello T, Matsumoto I, Sawada T, Allaman-Pillet N, Henry H, Beckmann JS, Hering BJ, and Bonny C
- Subjects
- Apoptosis drug effects, Base Sequence, DNA Primers, Gene Expression Regulation drug effects, Genes, fos genetics, Humans, Interleukin-1 pharmacology, Islets of Langerhans cytology, Islets of Langerhans drug effects, JNK Mitogen-Activated Protein Kinases metabolism, MAP Kinase Kinase 4, Mitogen-Activated Protein Kinase Kinases metabolism, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction, p38 Mitogen-Activated Protein Kinases metabolism, Cytokines pharmacology, Islets of Langerhans physiology
- Abstract
Pancreatic islet transplantation may successfully restore normoglycemia in type 1 diabetic patients. However, successful grafting requires transplantation of a sufficient number of islets, usually requiring two or more donors. During the isolation process and following clinical transplantation, islets are subjected to severe adverse conditions that impair survival and ultimately contribute to graft failure. Here, we have mapped the major intracellular stress-signaling pathways that may mediate human islet loss during isolation and following cytokine attack. We found that the isolation procedure potently recruits two pathways consisting of |mitogen-activated protein kinase kinase (MKK)7 --> Jun NH(2)-terminal kinase (JNK)/p38 --> c-fos| and the |nuclear factor-kappaB (NF-kappaB) --> iNOS| module. Cytokines activate the |NF-kappaB --> iNOS| and |MKK4/MKK3/6 --> JNK/p38| pathways without recruitment of c-fos. Culturing the islets for 48 h after isolation allows for the activated pathways to return to background levels, with expression of MKK7 becoming undetectable. These data indicate that isolation and cytokines recruit different death pathways. Therefore, strategies might be rationally developed to avoid possible synergistic activation of these pathways in mediating islet loss during isolation and following grafting.
- Published
- 2004
- Full Text
- View/download PDF
143. Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1.
- Author
-
Allaman-Pillet N, Størling J, Oberson A, Roduit R, Negri S, Sauser C, Nicod P, Beckmann JS, Schorderet DF, Mandrup-Poulsen T, and Bonny C
- Subjects
- Animals, Apoptosis, Base Sequence, Cell Line, DNA Primers, Down-Regulation, Humans, Hydrolysis, Islets of Langerhans cytology, Islets of Langerhans enzymology, Islets of Langerhans metabolism, Nuclear Proteins genetics, Point Mutation, Proteasome Endopeptidase Complex, Rats, Trans-Activators genetics, Ubiquitin metabolism, Adaptor Proteins, Signal Transducing, Calcium metabolism, Cysteine Endopeptidases metabolism, Multienzyme Complexes metabolism, Nuclear Proteins metabolism, Trans-Activators metabolism
- Abstract
In models of type 1 diabetes, cytokines induce pancreatic beta-cell death by apoptosis. This process seems to be facilitated by a reduction in the amount of the islet-brain 1/JNK interacting protein 1 (IB1/JIP1), a JNK-scaffold with an anti-apoptotic effect. A point mutation S59N at the N terminus of the scaffold, which segregates in diabetic patients, has the functional consequence of sensitizing cells to apoptotic stimuli. Neither the mechanisms leading to IB1/JIP1 down-regulation by cytokines nor the mechanisms leading to the decreased capacity of the S59N mutation to protect cells from apoptosis are understood. Here, we show that IB1/JIP1 stability is modulated by intracellular calcium. The effect of calcium depends upon JNK activation, which primes the scaffold for ubiquitination-mediated degradation via the proteasome machinery. Furthermore, we observe that the S59N mutation decreases IB1/JIP1 stability by sensitizing IB1/JIP1 to calcium- and proteasome-dependent degradation. These data indicate that calcium influx initiated by cytokines mediates ubiquitination and degradation of IB1/JIP1 and may, therefore, provide a link between calcium influx and JNK-mediated apoptosis in pancreatic beta-cells.
- Published
- 2003
- Full Text
- View/download PDF
144. [Inactivation of the X-chromosome in female mammals].
- Author
-
Allaman-Pillet N, Kaltenrieder V, Mathieu S, Bonny C, and Schorderet DF
- Subjects
- Animals, Female, Dosage Compensation, Genetic, Mammals genetics
- Published
- 2000
145. The 5' repeat elements of the mouse Xist gene inhibit the transcription of X-linked genes.
- Author
-
Allaman-Pillet N, Djemaï A, Bonny C, and Schorderet DF
- Subjects
- Animals, Base Sequence, Blotting, Northern, Blotting, Western, DNA Primers, Glucosephosphate Dehydrogenase genetics, Hypoxanthine Phosphoribosyltransferase genetics, Mice, Phosphoglycerate Kinase genetics, RNA, Long Noncoding, Reverse Transcriptase Polymerase Chain Reaction, Genetic Linkage, RNA, Untranslated genetics, Transcription Factors genetics, Transcription, Genetic genetics, X Chromosome
- Abstract
X chromosome inactivation in mammals requires the Xist gene, which is exclusively expressed from the inactive X chromosome (Xi). The large heterogeneous Xist nuclear RNA colocalizes with Xi, most likely through nuclear protein interactions. The 5' region of the Xist RNA contains a series of well-conserved tandem repeats known to bind heteronuclear proteins in vitro and to enhance human XIST transcription. We show in an in vitro system that the conserved repeat element located in the 5' region of the mouse Xist gene (Xcr) represses three X-linked genes but has no effect on the autosomal genes Aprt, Ins, and the viral SV40 gene. The repression effect is not mediated by the conserved core sequence (Ccs) of Xcr, but requires the presence of the complete Xcr. This Xcr effect on X-linked genes suggests that Xcr transcript recognizes the genes to be silenced and is involved in the spreading of X inactivation.
- Published
- 2000
- Full Text
- View/download PDF
146. Methylation status of CpG sites and methyl-CpG binding proteins are involved in the promoter regulation of the mouse Xist gene.
- Author
-
Allaman-Pillet N, Djemaï A, Bonny C, and Schorderet DF
- Subjects
- Animals, Azacitidine pharmacology, Base Sequence, Cell Line, Chloramphenicol O-Acetyltransferase, Cytosine, Female, Gene Expression Regulation, Male, Mice, Molecular Sequence Data, Mutagenesis, Site-Directed, Nuclear Proteins metabolism, RNA, Long Noncoding, Sequence Analysis, DNA, Thymine, X Chromosome, CpG Islands genetics, DNA Methylation drug effects, DNA-Binding Proteins metabolism, Promoter Regions, Genetic genetics, RNA, Untranslated, Transcription Factors genetics
- Abstract
The mouse Xist gene is expressed exclusively from the inactive X chromosome and is involved in the initiation of X inactivation. We previously reported that the -1157/+917 region of the Xist promoter was ubiquitously functional in mammalian cells and that experiments in a transient expression system revealed no trans-acting element responsible for the inactive X specific expression of Xist. In somatic tissues, the 5' end of the silent Xist allele on the active X is known to be fully methylated whereas the expressed allele on the inactive X is unmethylated. In the present study we have used a bisulphite genomic sequencing method to evaluate DNA methylation at all cytosines including CpG dinucleotides within the Xist promoter. We report and confirm that methylation of specific sites plays a key role in Xist gene expression. In vitro DNA methylation of the 5'-region drastically reduced transcriptional activity in transiently transfected fibroblasts. Mobility shift assays showed that methylation does not inhibit Xist promoter activity by preventing the binding of transcription factors and that two distinct nuclear proteins bind in a sequence methyl-CpG-specific manner. Therefore, we suggest that Xist repression involves its promoter methylation and two distinct methylated DNA binding proteins.
- Published
- 1998
147. Informative MspI polymorphism adjacent to exon 3 of the p16INK4 (MTS1) gene.
- Author
-
Chaubert P, Shaw P, and Pillet N
- Subjects
- Adult, Alleles, Cyclin-Dependent Kinase Inhibitor p16, Deoxyribonuclease HpaII, Gene Frequency, Genes, Tumor Suppressor, Humans, Carrier Proteins genetics, Exons, Polymorphism, Single-Stranded Conformational
- Published
- 1996
- Full Text
- View/download PDF
148. An acyclic 5-nitroindazole nucleoside analogue as ambiguous nucleoside.
- Author
-
Van Aerschot A, Rozenski J, Loakes D, Pillet N, Schepers G, and Herdewijn P
- Subjects
- Base Sequence, Molecular Sequence Data, Nucleic Acid Denaturation, DNA Probes chemistry, Indazoles chemistry, Nucleic Acid Conformation, Nucleosides chemistry, Oligodeoxyribonucleotides chemistry
- Abstract
Acyclic nucleoside analogues with carboxamido- or nitro-substituted heterocyclic bases have been evaluated for their possible use as universal bases in oligodeoxynucleotides. The acyclic moiety endows the constructs with enough flexibility to allow good base stacking. The 5-nitroindazole analogue afforded the most stable duplexes among the acyclic derivatives with the least spread in Tm versus the four natural bases. In spite of the acyclic moiety, stabilities are comparable with those of duplexes incorporating the recently described 5-nitroindole nucleoside analogue, but considerably exceed those for the 3-nitropyrrole analogue.
- Published
- 1995
- Full Text
- View/download PDF
149. [Diagnosis using PCR: the direct approach].
- Author
-
Schorderet DF and Pillet N
- Subjects
- Base Sequence, Cystic Fibrosis genetics, Fatty Acid Desaturases deficiency, Female, Genetic Diseases, Inborn diagnosis, Humans, Huntington Disease genetics, Lipid Metabolism, Inborn Errors genetics, Male, Molecular Sequence Data, Muscular Dystrophies genetics, Genetic Diseases, Inborn genetics, Polymerase Chain Reaction
- Abstract
The direct approach in molecular diagnosis proposes evidences of the mutations underlying the investigated diseases. Due to its speed, specificity and low cost, the Polymerase Chain Reaction (PCR) has become the method of choice in most of these analyses. The direct approach can be either positive or negative. In the first case, the diagnosis is based on the presence of a pathognomonic PCR product, while in the latter, it is the absence of such a product that makes the diagnosis possible. It is evident that both methods have to be validated by several control reactions. Examples out of daily practice illustrate various diagnostic areas.
- Published
- 1994
150. [Diagnosis using PCR: the indirect approach].
- Author
-
Pillet N and Schorderet DF
- Subjects
- Adenomatous Polyposis Coli genetics, Alleles, Base Sequence, Genetic Diseases, Inborn diagnosis, Genetic Linkage, Human Genome Project, Humans, Molecular Sequence Data, Pedigree, Genetic Diseases, Inborn genetics, Polymerase Chain Reaction
- Abstract
The goal of indirect molecular diagnostic techniques is the detection of a link between a specific allele of a polymorphic genomic marker and a given disease. This technique is used in two specific clinical situations: 1) when the gene is unknown and the search for a mutation or a gene product is impossible 2) when the gene is known but large and several mutations might be present. If none of the known mutations prevails in the local population the systematic and sequential search for every single mutation is not economical. A linkage study is required in those instances. The indirect analysis was up to the nineties based on markers detecting DNA-restriction fragments of various length. By the amplification of microsatellites by PCR the indirect approach has brought enormous progress. Together with the mapping by the Human Genome Project it will progress further. Although indirect molecular methodology can often avoid extended work it is only applicable to families with a member already affected by the disease. DNA from this individual is needed for the detection of a link of one allele to the disease. This means necessarily that the disease must be inherited and that the diagnosis is certain. Presymptomatic molecular diagnosis is illustrated by the analysis of a pedigree with familial adenomatous polyposis by microsatellite PCR techniques.
- Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.